Skip to content
10-Q

Quarterly Report

ALSERES PHARMACEUTICALS INC /DE

0001193125-13-225865

← back to feed
Filed
May 17, 2013 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2013 · Apr 30, 2013 30.64M sh
Stock Repurchased Q1 2013 · Mar 31, 2013 $28.22K
Capex Q1 2013 · Mar 31, 2013 $1.65M
Operating Cash Flow Q1 2013 · Mar 31, 2013 −$161.26M
Operating Cash Flow Q1 2013 · Mar 31, 2012 −$13.64K
Short Term Investments Q1 2013 · Mar 31, 2013 $166.87K
Short Term Investments Q1 2013 · Dec 31, 2012 $838.31K
Stockholders Equity Q1 2013 · Mar 31, 2013 −$26.8M
Stockholders Equity Q1 2013 · Dec 31, 2012 −$26.72M
Current Liabilities Q1 2013 · Mar 31, 2013 $9.55M
Current Liabilities Q1 2013 · Dec 31, 2012 $10.07M
Total Liabilities Q1 2013 · Mar 31, 2013 $26.78M
Total Liabilities Q1 2013 · Dec 31, 2012 $27.32M
Current Assets Q1 2013 · Mar 31, 2013 $290.65K
Current Assets Q1 2013 · Dec 31, 2012 $900.01K
Total Assets Q1 2013 · Mar 31, 2013 $354.24K
Total Assets Q1 2013 · Dec 31, 2012 $965.71K
Sga Expense Q1 2013 · Mar 31, 2013 $70.92M
Sga Expense Q1 2013 · Mar 31, 2012 $446.36K
Net Income Q1 2013 · Mar 31, 2013 −$198.99M
Net Income Q1 2013 · Mar 31, 2012 −$319.3K
Operating Income Q1 2013 · Mar 31, 2013 −$196.77M
Operating Income Q1 2013 · Mar 31, 2012 −$217.06K
Revenue Q1 2013 · Mar 31, 2013 $1.45M
Revenue Q1 2013 · Mar 31, 2012 $250K
Cash And Equivalents Q1 2013 · Mar 31, 2012 $122.2K
Cash And Equivalents Q1 2013 · Dec 31, 2011 $135.84K
Cash And Equivalents restated Q1 2013 · Mar 31, 2011 $92.86K